FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary... (atment of age-related macular degenerati...)

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry

Date:6/25/2008

atment of age-related macular degeneration (AMD), and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound, AKIi-5. This Quark compound is in a Phase I human clinical study for treatment of acute kidney injury.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

About RNAi

RNA interference (RNAi) is a Nobel Prize winning technology and one of the most exciting areas of drug discovery today. It represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products. RNAi could therefore offer a therapeutic approach to a broad range of diseases (cancer, infectious diseases, inherited diseases), many of which have been regarded as incurable and are not addressed by current therapeutics, therefore providing a large market opportunity.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward--looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related biology technology :

1. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
2. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
3. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
4. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
5. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
6. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
7. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
8. Medicare Approves in Home Sleep Apnea Testing
9. 3SBio Inc. Approves Share Repurchase Program
10. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
11. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder

Post Your Comments:

(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7

(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s

(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of

(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1

Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2 Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2 Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3 The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2 The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3 Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2 Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3

[0] Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results [0] Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators [0] The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference [0] Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies

...ANTIPOLIS, France, February 26 NicOx,S.A. (NYSE E...results for,full year 2008 and provided an overvie...ivities for naproxcinod, its lead investigational,...f osteoarthritis (OA). , Michele Garufi, Chief...e,NicOx has entered 2009 in its strongest strategi...

...o understand friction on a very small scale, a tea... to think big. , Friction is a force that affect...tact; the more surface contact there is, the stron...f a meter friction can wreak havoc on tiny device...les. With their high surface-to-volume ratio, nano...

... Feb. 25 Cornerstone Therapeutics Inc. (Nasdaq: ...d on developing and commercializing prescription m...ced that it will host a conference call at 8:30 AM...nancial results for the quarter and year ended Dec...pdate on the Company,s strategy, operations and pr...

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value Models present new view of nanoscale friction Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call

(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today

(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O

(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne

[0] Forest deal at Copenhagen must avoid creating 'carbon refugees'[0] CCNY professor foresees rising Antarctic snowmelt [0] Head and neck cancer survivors who use alcohol and cigarettes have increased death risk

...ading life scientists from Europe and around the w...ar Biology Organization (EMBO) for their proven ex..., distinguished as EMBO Members, are from Europe a...pected scientists come from other parts of the wor...rent membership total to 1360. , Membership is a ...

... Research , a journal of the American Association ...nicotine in breast tumor development and metastase...Beth Israel Deaconess Medical Center, is among the...ry cells. , "Although numerous studies indicate ...little is known about the effect of nicotine on br...

...other planets and in extreme environments on Earth...y initiative under a five-year grant from NASA,s A... Earth and Beyond." , Christopher H. House, assoc...isciplinary team to develop methods to detect and ...in relevant ecosystems in ancient rocks and other ...

Other Biology News:EMBO honors 59 leading life scientists 2 Study links nicotine with breast cancer growth and spread 2 Penn State receives new NASA astrobiology grant 2 Penn State receives new NASA astrobiology grant 3

EMBO honors 59 leading life scientists Study links nicotine with breast cancer growth and spread Penn State receives new NASA astrobiology grant

Criterion Staining and Blotting Trays, with lids, 12 from Bio-Rad

...orating a wide range of next-generation features i... standard for flexible laboratory solutions. It pu...tting, dilution, dispensing, and integrations int... flexible as it is efficient and economical. The B...

...ek FX P is the latest entry in the Biomek line. W... positional accuracy and increased robustness, it ...It can be configured with either one or two pipett... FX P sets the standard for flexible laboratory s...

BD Falcon 96-well Flat-bottom ELISA Plates from BD Biosciences - Discovery Labware

Biology Products:

Criterion Staining and Blotting Trays, with lids, 12 from Bio-Rad Biomek NX P Span-8 Laboratory Automation Workstation (w/ Gripper) from Beckman Coulter Biomek FXP Laboratory Automation Workstation with Single Span-8 Pod from Beckman Coulter BD Falcon 96-well Flat-bottom ELISA Plates from BD Biosciences - Discovery Labware

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary...(atment of age-related macular degenerati...)